Glycemic Gap Predicts Mortality in a Large Multicenter Cohort Hospitalized With COVID-19
Authors' conclusion
Relative hyperglycemia, as measured by the admission glycemic gap, is an important marker of mortality risk in COVID-19.
Study context
- Population
- Patients with diabetes or hyperglycemia (glucose > 10 mmol/L twice in 24 hours) hospitalized with COVID-19, March 2020–February 2021, 5 university hospitals in the eastern United States; 51.3% male, age 65.6 ± 14.4 years, BMI 31.5 ± 7.9 kg/m², HbA1c 8.07% ± 2.25%
- Participants
- 1,786 patients
- Outcome
- Mortality (also ICU admission and MV) during hospitalization
- Follow-up
- During hospitalization
Methodological details5 university hospitals
- 5 university hospitals
Main finding
As reported in the abstract
Mortality
Died during hospitalization
10.6%
Glycemic gap (admission glucose minus estimated average glucose based on HbA1c) as predictor of mortality, OR per mmol/L (95% CI 1.019, 1.061; P < 0.001); stronger predictor than admission glucose or HbA1c alone
1.040
Observational data: associations, not effects.
Further findings
Intensive care unit (ICU) admission and mechanical ventilation (MV) · during hospitalization
- Admitted to ICU
- 38.9%
- Received MV
- 22.9%
Original publication
Glycemic Gap Predicts Mortality in a Large Multicenter Cohort Hospitalized With COVID-19. J Clin Endocrinol Metab. Published 11 October 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →